Pharvaris (NASDAQ:PHVS) Shares Up 5.1%

Pharvaris (NASDAQ:PHVS)’s share price rose 5.1% on Monday . The company traded as high as $17.14 and last traded at $17.00. Approximately 52,495 shares traded hands during trading, a decline of 37% from the average daily volume of 82,686 shares. The stock had previously closed at $16.18.

Analysts Set New Price Targets

A number of equities research analysts recently commented on the company. JMP Securities increased their price target on Pharvaris from $49.00 to $50.00 and gave the company a “market outperform” rating in a research report on Thursday, April 11th. Oppenheimer raised their target price on shares of Pharvaris from $36.00 to $38.00 and gave the company an “outperform” rating in a research note on Wednesday, July 3rd. Morgan Stanley reissued an “overweight” rating and set a $34.00 price objective on shares of Pharvaris in a report on Monday, April 22nd. Finally, Wedbush reduced their target price on shares of Pharvaris from $35.00 to $31.00 and set an “outperform” rating for the company in a report on Thursday, May 9th. One research analyst has rated the stock with a sell rating and four have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $32.80.

Pharvaris Stock Performance

The company has a market capitalization of $548.28 million, a P/E ratio of -6.25 and a beta of -3.10. The firm has a 50 day moving average price of $17.91 and a two-hundred day moving average price of $22.13.

Pharvaris (NASDAQ:PHVS) last issued its quarterly earnings results on Wednesday, May 8th. The company reported ($0.56) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.56). On average, equities analysts expect that Pharvaris will post -2.39 earnings per share for the current year.

Institutional Trading of Pharvaris

Institutional investors and hedge funds have recently made changes to their positions in the company. venBio Partners LLC increased its position in shares of Pharvaris by 15.4% during the fourth quarter. venBio Partners LLC now owns 4,919,504 shares of the company’s stock valued at $137,992,000 after acquiring an additional 654,832 shares in the last quarter. Commodore Capital LP bought a new position in shares of Pharvaris during the 4th quarter worth approximately $22,440,000. Vivo Capital LLC acquired a new stake in Pharvaris during the 4th quarter valued at approximately $7,994,000. Finally, Blackstone Inc. acquired a new position in shares of Pharvaris in the fourth quarter worth about $2,805,000.

Pharvaris Company Profile

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial.